8-K: Cara Therapeutics Discontinues Oral Difelikefalin Program for Notalgia Paresthetica After Disappointing Trial Results

Cara Therapeutics has halted its clinical program for oral difelikefalin in notalgia paresthetica after the drug failed to show meaningful clinical benefit in a Phase 2/3 study.

Summary

• Cara Therapeutics has announced the results of the Part A of the KOURAGE-1 study, which evaluated oral difelikefalin for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
• The study was a Phase 2/3, two-part, multicenter, randomized, double-blind, placebo-controlled trial.
• In Part A, 214 patients were randomized into four groups receiving either 2 mg twice daily, 1 mg twice daily, 0.25 mg twice daily of oral difelikefalin, or a placebo for 8 weeks.
• The primary endpoint was the proportion of patients achieving a 4-point improvement from baseline in the weekly mean of the daily 24-hour Itch-Numeric Rating Scale (I-NRS) score at Week 8.
• The results showed that oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to the placebo.
• As a result, Cara Therapeutics has decided to discontinue the clinical program for oral difelikefalin in NP.
• The company will now explore strategic alternatives to maximize shareholder value.
• The drug was generally well tolerated with a safety profile similar to prior trials.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failure of the clinical trial and the discontinuation of the program. The company is now exploring strategic alternatives, which adds uncertainty.

Positives

• The drug was generally well tolerated with a safety profile similar to prior trials.
• The company has $70 million in cash, cash equivalents, and marketable securities as of March 31, 2024.

Negatives

• Oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo in the KOURAGE-1 study.
• The company has decided to discontinue the clinical program for oral difelikefalin in notalgia paresthetica (NP).

Risks

• The failure of the KOURAGE-1 study may negatively impact investor confidence.
• The company will need to explore strategic alternatives, which may involve uncertainty.
• The company is winding down the Phase 2/3 clinical program in NP, which may result in additional costs.

Future Outlook

The company will be winding down the Phase 2/3 clinical program in NP and exploring strategic alternatives focused on maximizing shareholder value. The company has stated that forward-looking statements are subject to risks and uncertainties.

Management Comments

• Christopher Posner, President and Chief Executive Officer of Cara Therapeutics, stated that they are disappointed that oral difelikefalin did not demonstrate a meaningful improvement in pruritus compared to placebo in the KOURAGE-1 Part A study.
• Management stated they are grateful for the patients and investigators who participated in the study.

Industry Context

This announcement highlights the challenges in developing effective treatments for pruritus and sensory neuropathies. The failure of oral difelikefalin in this trial may lead to increased scrutiny of other similar drug development programs in the industry.

Comparison to Industry Standards

• The failure of oral difelikefalin to show efficacy in this trial is a setback compared to other companies that have achieved positive results in similar clinical trials for pruritus.
• Companies such as Galderma and Trevi Therapeutics are developing treatments for pruritus, and their progress will be closely watched in light of Cara's results.
• The lack of efficacy in this trial contrasts with the success of Cara's IV formulation of difelikefalin, which is approved for pruritus associated with chronic kidney disease.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failure of the clinical trial and the discontinuation of the program.
• Employees involved in the NP program may be affected by the discontinuation of the program.
• Patients with notalgia paresthetica will not have this potential treatment option available.

Next Steps

• The company will wind down the Phase 2/3 clinical program in NP.
• Cara Therapeutics will explore strategic alternatives to maximize shareholder value.

Key Dates

Keywords

difelikefalin, pruritus, notalgia paresthetica, clinical trial, KOURAGE-1, Phase 2/3, biopharmaceutical, drug development